Meeting
2014 ASCO Annual Meeting
Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Authors
Eudocia Quant Lee
Dana-Farber Cancer Institute, Boston, MA
Eudocia Quant Lee , David A. Reardon , David Schiff , Jan Drappatz , Alona Muzikansky , Sean Aaron Grimm , Andrew David Norden , Lakshmi Nayak , Rameen Beroukhim , Mikael L. Rinne , Andrew S. Chi , Tracy Batchelor , Kelly Hempfling , Christine Sceppa McCluskey , Katrina H. Smith , Sarah C. Gaffey , Brendan Wrigley , Jeffrey J. Raizer , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00859222
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2020)
DOI
10.1200/jco.2014.32.15_suppl.2020
Abstract #
2020
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.
First Author: Eudocia Quant Lee
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah